Aquestive Therapeutics (AQST) Assets Average (2018 - 2026)

Aquestive Therapeutics' Assets Average history runs 9 years deep, the most recent figure standing at $150.8 million for Q1 2026.

• On a quarterly basis, Assets Average rose 48.07% year-over-year to $150.8 million in Q1 2026; TTM through Mar 2026 was $150.8 million, a 48.07% increase from a year earlier, with the FY2025 full-year figure at $130.9 million, up 64.85% from the prior year.
• Assets Average slipped to $150.8 million in Q1 2026 per AQST's latest filing, from $162.0 million in the prior quarter.
• Across five years, Assets Average topped out at $162.0 million in Q4 2025 and bottomed at $54.1 million in Q3 2022.
• The 5-year median for Assets Average is $93.5 million (2024), against an average of $90.4 million.
• Across the five-year window, Assets Average soared 108.94% in 2024 and slipped 20.72% in 2025, its largest moves.
• Year by year, Assets Average stood at $54.5 million in 2022, then climbed by 7.3% to $58.4 million in 2023, then surged by 80.88% to $105.7 million in 2024, then surged by 53.27% to $162.0 million in 2025, then decreased by 6.92% to $150.8 million in 2026.
• Per Business Quant, the three latest AQST Assets Average figures stand at $150.8 million (Q1 2026), $162.0 million (Q4 2025), and $128.6 million (Q3 2025).